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Cystic fibrosis (CF), a severe life-limiting disease, is associated with multi-organ
pathologies that contribute to a reduced exercise capacity. At present, the impact
of, and interaction between, disease progression and other age-related physiological
changes in CF on exercise capacity from child- to adult-hood is poorly understood.
Indeed, the influences of disease progression and aging are inherently linked, leading
to increasingly complex interactions. Thus, when interpreting age-related differences in
exercise tolerance and devising exercise-based therapies for those with CF, it is critical
to consider age-specific factors. Specifically, changes in lung function, chronic airway
colonization by increasingly pathogenic and drug-resistant bacteria, the frequency and
severity of pulmonary exacerbations, endocrine comorbidities, nutrition-related factors,
and CFTR (cystic fibrosis transmembrane conductance regulator protein) modulator
therapy, duration, and age of onset are important to consider. Accounting for how these
factors ultimately influence the ability to exercise is central to understanding exercise
impairments in individuals with CF, especially as the expected lifespan with CF continues
to increase with advancements in therapies. Further studies are required that account for
these factors and the changing landscape of CF in order to better understand how the
evolution of CF disease impacts exercise (in)tolerance across the lifespan and thereby
identify appropriate intervention targets and strategies.
Keywords: cystic fibrosis, pediatric, exercise capacity, aging, exercise prescription
INTRODUCTION AND OVERVIEW OF CYSTIC FIBROSIS
Cystic fibrosis (CF) is the most common genetic disease in the Caucasian population, caused by
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (Rowe et al.,
2005, 2016; Cutting, 2015; Ratjen et al., 2015; Elborn, 2016; Farrell et al., 2017). CF is a multisystem
disease affecting the pulmonary, gastrointestinal (GI), and reproductive systems, thereby resulting
in increased morbidity and mortality (Rowe et al., 2005, 2016; Ratjen et al., 2015; Stoltz et al.,
2015; Elborn, 2016). Defects in CFTR result in airway dehydration and the production of hyper-
viscous and acidic mucus, which contributes to defective mucociliary clearance (Fahy and Dickey,
2010; Peabody et al., 2018; Shei et al., 2018). As a consequence, the airways are prone to chronic
inflammation and recurrent infection, leading to a vicious cycle that causes progressive, irreversible
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lung damage and airway obstruction. The resulting pulmonary
disease, in combination with a host of other factors including
malnutrition (due to exocrine and endocrine pancreatic
insufficiency), physical inactivity, and intrinsic muscle
abnormalities, contribute to exercise intolerance in people
with CF (Marcotte et al., 1986b; Cox and Holland, 2017; Gruet
et al., 2017; Urquhart and Saynor, 2018).
Regular airway clearance and inhaled antibiotic therapy, in
combination with the recent development of highly effective
CFTR modulator therapies, have greatly extended the life
expectancy of people living with CF, allowing these patients to
live into, or indeed beyond, their fifth or sixth decade (Solomon
et al., 2015; De Boeck and Amaral, 2016; Quon and Rowe,
2016; De Boeck and Davies, 2017; Burgener and Moss, 2018;
McElvaney et al., 2018; Rubin, 2018; West and Flume, 2018). This
increased expected lifespan has highlighted the need to better
understand the evolution of people with CF as they reach ages
that were previously impossible or, at best, improbable. Indeed,
with age, secondary co-morbidities become more prominent
and prevalent. Specifically, co-morbidities such as chronic
infections from an ever-changing spectrum of pathogens, some
of which may become multi-drug resistant [i.e., Pseudomonas
aeruginosa (PsA), Burkholderia cepacia (B. cepacia), and atypical
mycobacteria, Figure 1A], and more frequent and severe
pulmonary exacerbations lead to a progressive lung function
decline and may, ultimately, increase mortality (Rowe et al.,
2005, 2016; Ratjen et al., 2015; Elborn, 2016). Furthermore,
this “aging CF population” has shown an increased incidence
of CF-related diabetes (CFRD), low bone mineral density, and
endothelial dysfunction due to chronic inflammation. In addition
to their system-specific effects, each of these co-morbidities have
deleterious consequences for quality of life (QoL) and aerobic
fitness. Given the high prognostic value of aerobic fitness for
mortality and QoL (Nixon et al., 1992; Moorcroft et al., 1997;
Pianosi et al., 2005; Ward et al., 2013; Vendrusculo et al.,
2018), understanding how exercise capacity changes, as well
as the impact of disease progression, as people with CF age,
may aid in developing appropriate, individually tailored exercise
recommendations, in improving adherence, and, ultimately, in
engendering better health outcomes in this population.
While it has long been established that children are not
simply “mini-adults,” this is particularly pertinent in clinical
populations in which aging occurs concomitantly, and potentially
interactively, with, but nonetheless distinctly from, disease
progression. Despite the importance of this distinction, the
majority of research has failed to account for the influence of age,
as well as the process and rate of aging, leading to potentially
misleading conclusions regarding the disease progression itself.
Indeed, comparisons between children and adults with CF are
further compounded by the very different treatment strategies
used in each age group – the treatment currently received by
children is likely to significantly alter the course of their disease
progression, and their experience of it, compared to that of those
who are now adults. Therefore, changes in disease pathology, co-
morbidities, disease complications, and treatment strategies as
patients with CF age must be carefully assessed when designing,
conducting and interpreting exercise studies in CF.
EXERCISE CAPACITY IN CF
Deficits in exercise capacity (i.e., the maximum amount of
physical exertion that a patient can sustain; (Goldstein, 1990) in
those with CF result from a combination of factors, including,
but not limited to, ventilatory dysfunction, changes in nutritional
status, abnormalities in peripheral muscles (i.e., muscle weakness
and putative metabolic abnormalities), cardiac constraint, and
disease-related deconditioning (Figure 2A). The mechanisms of
exercise limitation in CF have been reviewed elsewhere (Hulzebos
et al., 2015). Briefly, ventilatory dysfunction in CF may contribute
to exercise intolerance through deleterious changes in lung
function, dead space ventilation, respiratory muscle function,
ventilatory reserve, and ventilatory control. Together, these
ventilatory constraints may limit exercise tolerance, particularly
in more severe disease states. Specific to ventilatory dysfunction,
exercise-induced hypoxemia may be more prevalent in CF, at
least in part due to ventilation-perfusion mismatching secondary
to increases in physiologic dead space and intrapulmonary
arterio-venous shunting (Coffey et al., 1991). Nutritional status
also plays an important role in determining exercise limitation
in CF, particularly in those who are malnourished. Indeed,
malnutrition predisposes individuals with CF to loss of both
muscle mass and body fat, impaired diaphragmatic performance,
and negatively affects cardiac function (Marcotte et al., 1986a;
Lands et al., 1992a,b). Finally, muscle abnormalities including
muscle weakness, mitochondrial dysfunction, and altered muscle
metabolism may also contribute to exercise intolerance in CF
(de Meer et al., 1995; Meer et al., 1999; Divangahi et al.,
2009; Lamhonwah et al., 2010; Wells et al., 2011; Gruet et al.,
2016; Werkman et al., 2016; Gruet et al., 2017). Whilst the
mechanisms underpinning exercise limitation in those with
CF are complex and interdependent (Schöni and Casaulta-
Aebischer, 2000; Divangahi et al., 2009; Lamhonwah et al., 2010;
Pastré et al., 2014; Hulzebos et al., 2015; Jiang et al., 2016; Gruet
et al., 2017), it has been postulated that age-related progressions
in CF disease severity may be integral to the annual decrements
typically observed.
EFFECTS OF AGING ON EXERCISE IN CF
Despite evidence that exercise in people with CF improves
aerobic capacity and thereby reduces mortality (Radtke et al.,
2017), one of the most significant challenges is ensuring
engagement in habitual physical activity (White et al., 2007;
Myers, 2009). Indeed, engagement from a young age is imperative
as not only is this likely to attenuate the decline in fitness
and function and to promote the level from which this decline
occurs, but importantly, behaviors established during childhood
track into adulthood (Dishman et al., 1985). This therefore
highlights the need to instill healthy behaviors at an early age.
Recent case series reports regarding the influence of Orkambi R©,
one of the CFTR modulator combination therapies, on daily
physical activity and exercise tolerance over a 2 year period are
highly encouraging (Savi et al., 2019), especially when considered
in conjunction with reports of improvements in peak oxygen
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FIGURE 1 | Age-related decline in percent-predicted forced expiratory volume in 1 s (ppFEV1) in people with CF, stratified by birth cohort (A). Prevalence of
respiratory microorganisms by age cohort (B). Reprinted with permission from Cystic Fibrosis Foundation (2017).
consumption (V˙O2peak) and percent predicted forced expiratory
volume in 1 s (ppFEV1; Hatziagorou et al., 2018; Philipsen and
Pressler, 2018). Thus, as these therapies become more common
and are able to be initiated at younger ages, exercise capacity
may be preserved and/or improved in individuals with CF across
their lifespan. The question remains, nonetheless, whether these
individuals will be able to exercise normally or will still need
individually targeted exercise prescriptions due to a sub-normal
exercise capacity.
Children and adults with CF have been shown to have
a significantly lower V˙O2peak, lower gas-exchange threshold,
reduced work capacity, and reduced oxygen uptake efficiency
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FIGURE 2 | Determinants of exercise dysfunction in CF and age-related factors which may affect exercise capacity through the lifespan in CF (A). Airways in CF may
be altered in structure from fetal development or from destructive events, leading to airway malacia. The incidence and severity of factors involved in CF Pathology
increase over the lifespan of people with CF, as indicated by the progression from light yellow to dark orange across the lifespan in (A). Projected age-related decline
in aerobic capacity (i.e., V˙O2max ) for healthy populations (solid green line, adapted from Shvartz and Reibold (1990) and Booth and Zwetsloot (2010), and
hypothetical age-related declines in aerobic fitness for current (dashed blue line) and future (dotted red line) CF populations (B). It is possible that with early initiation
of CFTR modulator therapy and effective disease management, that in the future, individuals with CF may possess aerobic capacities more similar to healthy controls
than individuals with CF today.
compared to their healthy peers (Pouliou et al., 2001; Perpati
et al., 2010; Tomlinson et al., 2018). Similarly, a reduced time to
exhaustion during ramp testing (Saynor et al., 2016), impaired
blood flow regulation, and an exaggerated oxidative stress and
slower oxygen uptake response to submaximal exercise have been
shown in children with CF (Tucker et al., 2018). While these
impairments in exercise capacity are evident from a young age
in CF and persist into adulthood, it is not yet known whether
the differences between CF and healthy controls may become
more pronounced with age. Indeed, no studies have sought to
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directly compare the exercise capacity of children and adults
with CF. However, it is pertinent to note that such comparisons
may be complicated by changes in pharmacological and non-
pharmacological treatment strategies over the last few decades.
Therefore, longitudinal studies that account for patient variations
in treatment strategies are required; the increasing availability
and utilization of cardiopulmonary exercise testing during annual
reviews will be instrumental in capturing this information. In
healthy populations, maximal oxygen consumption V˙O2max is
known to decline with age, although regular exercise can slow
this decline (Figure 2B – including hypothetical projected age-
related declines for CF populations; Hagberg, 1987; Hawkins and
Wiswell, 2003). The magnitude and rate of decline in V˙O2max in
those with CF due to an accelerated ageing process still remains
to be disentangled from the influence of CF per se.
Bacterial Colonization
One of the most prominent differences between children and
adults with CF is the degree and consistency of pulmonary
colonization. Patient Registry data from the US Cystic Fibrosis
Foundation shows that children under the age of 17 years
tend to be colonized predominantly with Staphylococcus aureus
(S. aureus), methicillin-resistant S. aureus, and Haemophilus
influenzae, whilst adults have a larger percentage of PsA and
an increase in the proportion of Stenotrophomonas maltophilia
and B. cepacia (Figure 1B; Parkins and Floto, 2015; Cystic
Fibrosis Foundation, 2017). Recurrent and increasingly persistent
respiratory infections in youth, along with viral and fungal
infections, contribute to repeated pulmonary damage, and as
the disease progresses, these people with CF become more
susceptible to colonization and infection with gram-negative
bacteria, including multidrug resistant PsA (Elborn, 2016;
Winstanley et al., 2016).
Recurrent and difficult to treat pulmonary infections are
major determinants of progressive pulmonary decline over
the lifespan, which coincides with progressive loss of exercise
capacity (Rowe et al., 2005, 2016; Ratjen et al., 2015; Elborn,
2016; Radtke et al., 2017). Deteriorating lung function itself can
contribute to airflow limitation, ventilatory-perfusion mismatch,
predisposition to desaturation during exercise, and respiratory
muscle weakness, all of which have profound impacts on exercise
capacity. However, despite impaired exercise capacity being a
common characteristic of CF, the underpinning physiological
mechanisms are generally unknown. It is therefore unsurprising
that studies and reviews incorporating children, adolescents, and
adults with CF have failed to consider how age mediates, or
impacts, exercise capacity (Radtke et al., 2017; Abdelbasset et al.,
2018). Nonetheless, recent research has shown that even young
children, with fewer exacerbations, had a lower exercise capacity
in comparison to healthy counterparts. Indeed, Abdelbasset
et al. (2018) found that CF children’s V˙O2peak was significantly
correlated with quadriceps strength and endurance. Therefore,
the function of the peripheral muscles may play a significant role
in the decreased exercise capacity in children with CF (Ferrari
et al., 2015; Gruet et al., 2017). In adults with CF, the strength
of the quadriceps has been associated with aerobic capacity and
lung function, with those with airway obstruction unable to
undertake continuous exercise due to lower extremity fatigue
(Moorcroft et al., 2005). Across the age spectrum, Troosters
et al. (2009) reported reduced skeletal muscle strength and
endurance of those with CF, which was associated with decreased
exercise capacity and subsequent clinical complications. This
has been postulated to be associated with early neuromuscular
activity deteriorations in the quadriceps, as observed following
high-intensity aerobic exercise in chronic obstructive pulmonary
disease (COPD) (Mador et al., 2000), although it should be noted
that the pathophysiologic basis for this may differ between COPD
and CF. Therefore, when designing, conducting, and evaluating
exercise physiology studies in CF, it is important to not only
account for age, but the associated changes in colonization and
systemic inflammation, which can be markedly different across
age groups in CF.
Frequency of Pulmonary Exacerbations
and Hospitalization
Progression of CF lung disease with age contributes substantially
to the more frequent occurrence of pulmonary exacerbations
and consequent hospitalizations. Importantly, during
hospitalizations for acute pulmonary exacerbations, physical
activity is reduced or even absent (Ward et al., 2013). This may
be due, at least in part, to a lack of access to exercise facilities (due
to infection control measures; (Saiman et al., 2014), in addition
to the pulmonary symptoms and associated treatments resulting
from the exacerbation itself. When aerobic exercise is conducted
during hospital admissions in children with CF, a substantially
improved V˙O2max has been reported at discharge (Selvadurai
et al., 2002), highlighting the importance of maintaining
physical activity, irrespective of form (i.e., exercise), during
hospitalization. The increased frequency of hospitalizations
in adulthood likely contributes to declining physical activity
during, and immediately following, these episodes. Any decline
in physical activity levels could impact on the ability to complete
activities of daily living, accelerate their decline in pulmonary
function, and deteriorate QoL in those with CF (Wilkes et al.,
2009; Dwyer et al., 2011).
Nutrition
Nutrition is increasingly recognized as a key determinant of
physical, mental and social health across the lifespan, especially
for people with CF. Because CFTR is abundantly expressed in
the exocrine pancreatic and biliary secretory system, mutations
in CFTR can result in mucus obstruction in these organs
and consequent exocrine pancreatic insufficiency (Rowe et al.,
2005, 2016; Ratjen et al., 2015; Elborn, 2016). Thus, prominent
GI manifestations of CF disease are evident, resulting in
malabsorption of fat, secondary nutritional loss, malabsorption
and deficiency of fat-soluble vitamins, chronic gastro-esophageal
reflux, and susceptibility to recurrent small bowel obstruction.
Progressive damage to the endocrine pancreas, resulting from
protein accumulation (consequent to CFTR dysfunction) and
precipitation within the pancreatic ducts that causes ductal
destruction and ischemic damage (Laguna et al., 2010; Gibson-
Corley et al., 2016), leads to the occurrence of CFRD in a majority
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of individuals with CF, which is clinically distinct from traditional
Type 1 and Type 2 diabetes mellitus in non-CF populations. The
prevalence of CFRD increases across the lifespan, from 2% in
children to 19% in adolescents and 50% in adults (≥18 years)
living with CF (Moran et al., 2010; Lewis et al., 2015); over 90% of
pancreatic insufficient CF patients have CFRD by approximately
50 years old. Thus, CFRD is an important comorbidity, which
becomes more prevalent with age and may contribute to the loss
of exercise capacity. Exercise training has been shown to improve
glycemic control in CF (Beaudoin et al., 2017), highlighting
nutrition not only as a determinant of exercise capacity but also a
potential area of benefit from regular exercise training.
CF-related diabetes is highly relevant given that malnutrition,
weight loss, and lean muscle mass loss all contribute to exercise
intolerance. Moreover, CFRD also negatively impacts pulmonary
function and, consequently, morbidity and mortality (Chase
et al., 1979; Milla et al., 2000; Pencharz and Durie, 2000;
Borowitz et al., 2002; Sinaasappel et al., 2002; Milla, 2007;
Moran et al., 2010; Lewis et al., 2015; Wolfe and Collins, 2017;
Collins, 2018; Rozga and Handu, 2019). Lung bacterial clearance
is negatively affected by hyperglycemia with hyperglycemia
contributing to increases in inflammation and infection (Brennan
et al., 2007; Hunt et al., 2014), which may partially account
for these CFRD sequelae. CFRD and malnutrition may affect
exercise capacity most directly by predisposing patients toward
lean muscle mass loss, atrophy, and cachexia, particularly
when nutritional needs are not adequately met. Furthermore,
secondary morbidities associated with uncontrolled CFRD, such
as neuropathy, nephropathy and retinopathy, can have additional
deleterious effects on exercise capacity and QoL (Rosenecker
et al., 2001; Laguna et al., 2010). Specifically, these deleterious
effects are mediated by factors including, but not limited to: loss
of balance, coordination, reflexes, and muscle weakness resulting
from diabetic neuropathy; impaired blood pressure control,
nausea, and vomiting, fatigue, peripheral edema and potentially
progression to renal failure resulting from diabetic nephropathy;
and blurred vision, glaucoma, cataracts, and macular edema
resulting from diabetic retinopathy. Furthermore, underweight
patients (BMI< 18 kg m−2) can experience a sustained catabolic
state resulting, in part, from prolonged malnutrition, ultimately
resulting in chronic weight loss and difficulty maintaining or
gaining weight, which negatively affects lung function. This
clinical presentation can adversely affect lean muscle mass,
contribute to muscular atrophy and cachexia, and inadequate
bioenergetic stores to support exercise. Indeed, malnutrition
is increasingly observed throughout maturity, with growing
recognition that a low-fat free mass may be hidden by a normal,
or elevated, BMI. Therefore, proper management of nutrition
in CF (and of CFRD in individuals who present with it) is
an important method to preserve or even enhance, exercise
capacity. At present, however, exercise nutrition guidelines
specific to the CF population are not available, and the
most recent clinical nutrition guidelines (Turck et al., 2016;
Rozga and Handu, 2019) do not address exercise nutrition
in CF. We therefore suggest that future research seek to
address the unique nutritional needs of individuals with CF
during exercise.
While it is still important to consider the nutritional status
in pediatric individuals with CF, the acute and chronic effects
of malnutrition become more evident with age partially due to
increasing chronic inflammation and infections, and therefore
require more interventions to manage. Such interventions may
include the use of percutaneous endoscopic gastric feeding
tubes, peripherally inserted central catheters and/or ports, all of
which may represent barriers to exercise. For example, anecdotal
evidence suggests that patients with feeding tubes experience pain
in the abdominal muscles during workouts, which may prevent
them from engaging in core-strengthening exercises, or dynamic
exercises which require significant activation of the core muscles.
It is also important to consider the socioecological factors
associated with such interventions, especially in young pre-
pubertal and pubertal CF populations, which further predispose
them to avoid physical activity.
Biological Maturation
There is contradicting evidence regarding whether biological
maturation, most commonly assessed through age at peak height
velocity (PHV) and age at menarche, is delayed in youth with
CF (Johannesson et al., 1997; Aswani et al., 2003; Bournez et al.,
2012; Scaparrotta et al., 2012; Sands et al., 2015). Specifically,
while the rate of PHV and final height are suggested to be
lower in people with CF compared to their healthy peers, it
is still equivocal whether the age of onset of puberty is also
different in CF. Alterations in biological maturation could be
the result of nutritional factors, the use of corticosteroids, and
differences in sex hormone secretion (e.g., androgen secretion,
which is known to be ergogenic), each of which have been
suggested to be abnormal in CF. Regardless of etiology, in
CF, delayed biological maturation may influence the evolution
of exercise capacity as patients age, especially with respect to
sex hormone secretion, which is an important determinant of
exercise capacity (Kindermann et al., 1982; Ogawa et al., 1992;
Sheel et al., 2004; Molgat-Seon et al., 2018), and should thus be
considered in exercise studies of people with CF. In particular,
sex hormone secretion may influence the onset of puberty, rate
of maturity, and in non-CF children, sex differences in exercise
capacity exist even in pre-pubescent children. Whether the CF
population exhibits more or less pronounced sex differences
in exercise capacity is, however, presently unknown. Limited
evidence suggests that adult and adolescent females with CF have
lower physical fitness compared with males when matched for
disease severity, however, it is presently unknown whether this
is related to pathophysiology, behavior, or both, and whether
these findings may extend to youth (Eisenstadt et al., 2016).
Differences in the onset and rate of maturity are also likely to have
social implications with regards to peer perceptions that influence
engagement in physical activity and exercise.
Treatment Strategies for Children and
Adults With CF
The advent of CFTR modulator therapies has revolutionized the
treatment of CF. These therapies can be broadly divided into
CFTR potentiators, which improve ion and fluid conductance
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through the CFTR channel, and CFTR correctors, which aid in
chaperoning mutated CFTR proteins during protein folding,
thereby preventing endoplasmic reticulum (ER)-mediated
degradation (Burgener and Moss, 2018; McElvaney et al., 2018;
Habib et al., 2019). Currently approved therapies cover roughly
40% of individuals with CF, depending on age and mutation class
(Cystic Fibrosis Foundation, 2017), and ongoing Phase 3 clinical
trials of triple-combination therapies have the potential to extend
that coverage to roughly 90% of people with CF (Davies et al.,
2018; Holguin, 2018; Keating et al., 2018; Vertex Pharmaceuticals
Incorporated, 2018a,b). Moreover, several ongoing trials are
evaluating the use of CFTR modulator therapies in infants and
toddlers (ranging from 0 to 24 months) with CF (Cystic Fibrosis
Foundation, 2017). If successful, these trials will enable early
initiation of highly effective CFTR modulator therapy, which has
the potential to preserve pulmonary function at near-normal
levels, and to arrest the annual decline in lung function that is
currently characteristic of CF. This may, in turn, create a new
“generation” of individuals with CF whose disease course is
markedly different from the current CF population who may
only have initiated CFTR modulator therapy after significant
lung damage had already occurred. It is therefore postulated
that such early intervention and preservation of lung function
would substantially improve individuals’ exercise capacity by
abrogating ventilatory dysfunction.
The age at which people with CF begin CFTR modulator
therapy can have a profound effect on the disease course, and
consequently, both morbidity and mortality. Most prominently,
improvements in pulmonary function, as well as arresting
the rate of decline in pulmonary function, greatly improve
clinical outcomes, QoL, and the ability to exercise. The effects
of CFTR modulator therapies on extra-pulmonary CF disease
manifestations are less clear, and, in particular, it is still unclear
whether CFTR modulators can improve diabetic status (Bellin
et al., 2013; Tsabari et al., 2016; Thomassen et al., 2018; Kelly
et al., 2019; Li et al., 2019). Nonetheless, CFTR modulator
therapies have been shown to have a positive effect on weight
gain and body mass index (Gelfond et al., 2017; Houwen
et al., 2017; Gifford et al., 2018; Stallings et al., 2018), which
might be beneficial for exercise capacity in malnourished or
undernourished individuals with CF. Other therapies that help
manage symptoms and sequelae of CF, such as inhaled hypertonic
saline, airway clearance therapies, inhaled mucolytics, anti-
inflammatories, and anti-microbials, may also vary in their use
across the CF lifespan. For example, a recent investigation found
that inhaled hypertonic saline could safely be used in infants
with CF (Stahl et al., 2019), therefore enabling early intervention,
which may aid in preserving lung function and slowing disease
progression. It is clear, however, that when appropriate, the
younger individuals with CF are when the treatment is initiated
and the better these treatments are maintained, the better the
clinical outcomes, morbidity and QoL (Davies et al., 2016;
Rosenfeld et al., 2018). It also remains to be elucidated how the
use of these therapies, and the age at which they are initiated,
affects exercise capacity, physical activity levels and how to
account for differences between individuals with CF in these
regards when designing and analyzing exercise and physical
activity studies. However, based on the clinical efficacy of these
therapies, it is likely that early initiation of CFTR modulator
therapy, effective symptom management and infection control,
and regular airway clearance therapy all enhance the ability of
individuals with CF to exercise. Thus, future studies should aim
to determine how and to what extent these therapies are beneficial
for exercise, and also control for the use of these therapies when
classifying the CF population.
LIMITATIONS IN COMPARING
CHILDREN AND ADULTS WITH CF
Overall, the progression of disease throughout the lifespan
produces marked differences between children and adults with
CF. It is therefore important to consider age-specific differences
when interpreting exercise studies in these populations.
Importantly, as those with CF age, they experience progressive
declines in pulmonary function and increases in the incidence
and prevalence of co-morbidities, both of which ultimately
contribute to reduced exercise capacity. That is not to say
that children with CF do not also possess reduced exercise
capacity, however, the etiology of exercise impairment appears
to be more complex in adults. Thus, when designing and
conducting exercise studies in CF, it is important to ensure that
appropriate descriptive measures which encompass these factors
are employed, and that analyses control for, or account for, these
factors. These types of analyses may require multivariate or
mixed-model designs, thus it becomes important for researchers
to include methodologists and biostatisticians in order to ensure
both the design and analysis of exercise studies are appropriate
and account for potential modifiers of exercise capacity that
are unique to CF.
In addition to careful consideration of study design and
analysis, the changes in pathophysiology across the lifespan in
CF also highlights the need to conduct studies in both pediatric
and adult populations including eras before and after initiation of
CFTR modulator therapies, and not to simply use one population
to draw conclusions about the overall CF population. It is clear
that these populations are physiologically unique beyond simply
being different in age. Therefore, understanding the differences
in exercise physiology and pathophysiology in children vs. adults
in CF may provide insight into how disease progression affects
exercise intolerance. This information may aid in designing
appropriate interventions and exercise prescription to reduce the
decline in exercise capacity and improve patient health.
Presently, exercise training and testing are recommended
for individuals with CF (Dwyer et al., 2011; Hebestreit et al.,
2015; Radtke et al., 2017; Hebestreit et al., 2018; Urquhart
and Saynor, 2018; Cox and Holland, 2019). However, specific
recommendations for exercise prescription need to be developed
further, and a recent systematic review on physical exercise
training for CF concluded that the moderate quality of current
evidence and small size, duration, and incomplete reporting
of studies limits conclusions about the efficacy of physical
exercise training for CF (Radtke et al., 2017). Future large,
high-quality studies, including randomized controlled studies,
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are necessary to determine the optimal training components
(including exercise modality, frequency, intensity, and duration)
for individuals with CF (Radtke et al., 2017). In addition, we
recommend future studies account for the factors discussed in
this review, in order to better control for differences in age,
disease progression, nutritional status, and other factors which
may impact exercise capacity.
CONCLUSION
In summary, disease progression in CF from childhood
through adolescence to adulthood leads to progressively more
complex exercise intolerance and provides a unique model
to study differences in exercise capacity across the lifespan
of individuals with CF. When undertaking exercise studies
in CF, it is critically important to consider factors such as
declining pulmonary function, increased chronic colonization
by increasingly pathogenic and drug-resistant bacteria, increased
frequency and severity of pulmonary exacerbations, endocrine
comorbidities, nutritionally related factors, and modulator
therapy. In particular, accounting for how these factors ultimately
influence the ability to exercise is important to better understand
exercise impairments in individuals with CF. As the expected
lifespan with CF continues to increase with advancements in
therapies, it is also important to better understand how these
factors evolve over the lifespan as individuals with CF age,
and to clarify how adult and pediatric populations differ. It is
therefore important to conduct studies in both pediatric and
adult populations to account for age-related differences and
better understand how the evolution of CF disease impacts
exercise (in)tolerance across the lifespan. Moreover, longitudinal
studies of CF patients who begin CFTR modulator therapy early
in life may also aid in understanding how arresting disease
progression early in life affects exercise capacity over the lifespan
of these patients.
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